Beth Fand Incollingo
CURE Magazine
Central Jersey, NJ, United States
Contact Beth
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Beth:
One Man's Journey with Testicular Cancer Inspired Him to Share Jokes with Others
One man discovered that his experience with testicular cancer inspired jokes he could share with others. → Read More
Brukinsa May Cause Fewer Side Effects Than Other BTK Inhibitors for Patients with B-Cell Malignancies
A clinical trial of Brukinsa (zanubrutinib) is open to patients with B-cell blood cancers and will determine whether the side effects re-emerge with Brukinsa. → Read More
CancerCare Offers Online Support to Lesbian, Gay, Bisexual, Transgender and Questioning and/or Queer People
CancerCare unveils its new online support for members of the LGBTQ+ community who also have cancer. → Read More
CURE Pandemic Profiles: A Time to Grow
For survivor Michele Grimes, time at home during the pandemic fosters an opportunity for reflection and growth. → Read More
Looking at Immunotherapies for Patients with Metastatic Prostate Cancer
Immunotherapy could help a segment of patients with metastatic prostate cancer, a study found. → Read More
A Matter of Acceptance
One survivor has advice for others affected by both cancer and the COVID-19 pandemic: Accept your limitations. → Read More
FDA Approves Tecentriq Immunotherapy For Certain Non-Small Cell Lung Cancers
Tecentriq is approved as an initial treatment for non-small cell lung cancer that has spread and expresses the protein PD-L1 but does not have alterations in the EGFR or ALK genes. → Read More
Cancer Mortality Rate Declined More Steeply in States That Expanded Medicaid Under the Affordable Care Act
The cancer mortality rate declined more in states that expanded Medicaid coverage than those that didn’t following the passage of the Affordable Care Act of 2010, a study found. → Read More
FDA Approves Combination of Lynparza and Avastin as Maintenance Treatment for Advanced Ovarian Cancer
Lynparza and Avastin are now approved for patients with advanced ovarian cancer that carries a specific mutation and has responded to previous treatment with platinum-based chemotherapy plus Avastin. → Read More
Following the Clues With Liquid Biopsies
Liquid biopsies may reveal who needs treatment for recurrent breast cancer — and, just as important, who doesn’t. → Read More
Lasting Love
“Lasting Love” shares a moving and constructive message that may help support youngsters as they navigate a deep loss. → Read More
Making It Personal With Waldenstrom's Macroglobulinemia
Treating relapsed Waldenstrom’s macroglobulinemia takes an individualized approach from a growing list of options. → Read More
A Look Inside a Supportive Care Clinic
This one-stop shop offers patients pain-management strategies, emotional support, nutritional guidance and more. → Read More
Lymphadenectomy in Ovarian Cancer: The Case for Staying in Place
Removing lymph nodes that appear unaffected by ovarian cancer won’t help and might hurt. → Read More
Mutations Matter: Cholangiocarcinoma Tumor Profiling Awareness
Through community outreach, the Cholangiocarcinoma Foundation aims to increase tumor profiling and clinical trial participation. → Read More
Feel More Like You
Walgreens expands health and beauty support program for patients with cancer. → Read More
Tutu Good
The Tutu Project uses unique landscape photos to raise money for patients with breast cancer. → Read More
Sweet Surrender: Will Cutting Out Sugar Help You Prevent Cancer?
Banishing sugar and extra body fat can be important tools in preventing cancer. → Read More
Screening and Education Are Crucial to the Prevention and Early Diagnosis of Cholangiocarcinoma
Targeted drugs and immunotherapies are still on the horizon for people with cholangiocarcinoma, or bile duct cancer. → Read More
Investigational BTK Inhibitor Sparks Responses in Patients with Mantle Cell Lymphoma
The investigational targeted drug zanubrutinib (BGB-3111) appeared to be highly active, inducing an overall response rate of 83.5 percent in patients with relapsed/refractory mantle cell lymphoma, who were treated in a single-arm, open-label, multicenter, phase 2 trial. → Read More